Evoke Pharma Inc (EVOK)
0.5199
+0.04
(+8.58%)
USD |
NASDAQ |
Apr 19, 16:00
0.5199
0.00 (0.00%)
After-Hours: 20:00
Evoke Pharma Enterprise Value: 4.320M for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 4.320M |
| April 17, 2024 | 4.915M |
| April 16, 2024 | 4.245M |
| April 15, 2024 | 4.289M |
| April 12, 2024 | 4.584M |
| April 11, 2024 | 4.839M |
| April 10, 2024 | 5.156M |
| April 09, 2024 | 4.754M |
| April 08, 2024 | 5.008M |
| April 05, 2024 | 5.223M |
| April 04, 2024 | 5.391M |
| April 03, 2024 | 5.517M |
| April 02, 2024 | 5.456M |
| April 01, 2024 | 5.262M |
| March 28, 2024 | 5.432M |
| March 27, 2024 | 5.235M |
| March 26, 2024 | 5.387M |
| March 25, 2024 | 5.262M |
| March 22, 2024 | 5.364M |
| March 21, 2024 | 5.262M |
| March 20, 2024 | 5.288M |
| March 19, 2024 | 5.424M |
| March 18, 2024 | 5.517M |
| March 15, 2024 | 5.517M |
| March 14, 2024 | 5.980M |
| Date | Value |
|---|---|
| March 13, 2024 | 5.695M |
| March 12, 2024 | 5.771M |
| March 11, 2024 | 5.814M |
| March 08, 2024 | 6.195M |
| March 07, 2024 | 6.153M |
| March 06, 2024 | 6.026M |
| March 05, 2024 | 6.017M |
| March 04, 2024 | 5.898M |
| March 01, 2024 | 5.771M |
| February 29, 2024 | 5.872M |
| February 28, 2024 | 5.517M |
| February 27, 2024 | 5.608M |
| February 26, 2024 | 5.601M |
| February 23, 2024 | 5.696M |
| February 22, 2024 | 5.932M |
| February 21, 2024 | 6.017M |
| February 20, 2024 | 6.109M |
| February 16, 2024 | 6.026M |
| February 15, 2024 | 6.195M |
| February 14, 2024 | 6.248M |
| February 13, 2024 | 5.972M |
| February 12, 2024 | 2.571M |
| February 09, 2024 | 2.751M |
| February 08, 2024 | 2.408M |
| February 07, 2024 | 2.439M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-2.545M
Minimum
Nov 22 2022
142.38M
Maximum
Aug 14 2020
26.50M
Average
13.68M
Median
Oct 23 2019
Enterprise Value Benchmarks
| Eton Pharmaceuticals Inc | 62.60M |
| NovaBay Pharmaceuticals Inc | 2.485M |
| Palatin Technologies Inc | 21.01M |
| iBio Inc | 16.03M |
| Theriva Biologics Inc | -12.54M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.987M |
| Revenue (Quarterly) | 1.676M |
| Total Expenses (Quarterly) | 3.564M |
| EPS Diluted (Quarterly) | -0.59 |
| Gross Profit Margin (Quarterly) | 96.48% |
| Profit Margin (Quarterly) | -118.6% |
| Earnings Yield | -448.2% |
| Normalized Earnings Yield | -448.16 |